AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 181-200 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
181
Earth Eye Co
lowweak
Opp 2
Risk 3

Thesis: The reviewed sources only indicates Earth Eye Co is a Chinese private company associated with the TEE-01B surveillance satellite used for imaging and surveillance. This suggests some asset relevance in Earth observation, but there is no direct business traction or positive catalyst evidence available.

Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite.

Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty.

182
Exquadrum, Inc.
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources rationale describes Exquadrum as a rocket-maker acquired by Mach Industries, which at least indicates strategic relevance to launch/propulsion capabilities if the acquisition meaningfully advances commercialization (: no provided in reviewed sources).

Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence.

183
Fergani Space
lowweak
Opp 2
Risk 2

Thesis: Reviewed evidence rationale suggests Fergani Space launched a fifth test satellite into LEO with communications and navigation capabilities, which could indicate technical progress if still current, but no direct post-recent evidence window evidence are available to support a durable 1 year+ opportunity thesis.

Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report.

Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence.

184
Filtronic PLC
lowweak
Opp 2
Risk 1

Thesis: Older reviewed sources context says Filtronic is in a space/satellite communications context and has a SpaceX deal via article, which could be positive if current, but there is no retained in-window direct positive evidence with to justify a stronger ranking.

Why now: There is no evidenced near-term or durable why-now catalyst inside the retained 90-day evidence window.

Caveats: Reviewed evidence references but provides no representative article. Potentially positive older context may be stale or superseded; recency cannot be validated. No retained evidence after recent evidence window.

185
GalaxEye Space
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources membership rationale describes GalaxEye as launching Mission Drishti, an OptoSAR satellite with defense and disaster-response use cases, which is strategically interesting, but no within the recent evidence window direct evidence is available to support a stronger ranked opportunity.

Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence.

Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately.

186
GALVANY
lowweak
Opp 2
Risk 2

Thesis: The membership rationale says GALVANY raised a €10M seed in a European tech funding roundup, which is at least a financing signal that could support future execution. However, the reviewed sources explicitly says funding alone is insufficient without a clear space linkage, and there are no available direct evidence after recent evidence window.

Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit.

187
GEOST
lowweak
Opp 2
Risk 2

Thesis: GEOST may retain strategic relevance through its cited prototype development role in space domain awareness and the note that it is now Rocket Lab Optical Systems after acquisition, but the reviewed sources provide no retained recent evidence window-window evidence to support a current standalone upside thesis.

Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank.

Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business.

188
GHGSat
lowweak
Opp 2
Risk 2

Thesis: GHGSat likely has strategic relevance as a commercial greenhouse-gas monitoring satellite company, but the reviewed sources includes no available dated evidence to support a stronger opportunity ranking.

Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view.

Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence.

189
Globalstar
lowweak
Opp 2
Risk 2

Thesis: Globalstar is described in membership rationale as a satellite communications and direct-to-device company, but the reviewed sources includes no available within the recent evidence window positive evidence to support a stronger ranked opportunity view.

Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence.

190
Guoxing Aerospace Technology
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources rationale says Tencent partners with Guoxing Aerospace for Star Computing AI cloud in an article about space-based AI computing, which could imply exposure to a longer-horizon emerging segment if substantiated by direct evidence (: no provided in reviewed sources).

Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact.

191
HawkEye 360, Inc.
lowweak
Opp 2
Risk 1

Thesis: The reviewed sources membership rationale says HawkEye 360 provides RF intelligence/data services and has government-linked business, which could support a durable demand thesis, but no within the recent evidence window evidence or article summaries are available to justify a stronger score.

Why now: There is no available post-recent evidence window evidence in the reviewed sources to establish a current catalyst or changed business state.

Caveats: No evidence available after recent evidence window. Cannot rely on membership rationale alone for direction.

192
HawkEye 360, Inc.
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources indicates HawkEye 360 is a space intelligence company with a satellite constellation and government-contract exposure, which could be attractive over a multi-year horizon if contract flow and constellation utilization continue.

Why now: The only retained dated item is an April 5, 2026 supporting article context entry stating HawkEye 360 is a data analytics company developing space-based radio frequency mapping and a satellite constellation startup: That is too weak to establish a strong current catalyst.

Caveats: Only weak supporting article context is retained after recent evidence window; no direct event/fact evidence is available. Phase2 rationale mentions 30+ satellites and government contracts, but the reviewed sources does not provide those source articles in detail here.

193
Innoseis
lowweak
Opp 2
Risk 1

Thesis: Innoseis has the strongest limited positive context in this screen because the membership rationale says it raised €6M and has applications in space exploration, with technology selected for future Moon measurements, which could support a long-horizon opportunity if substantiated by direct evidence (: unavailable in reviewed sources). However, the reviewed sources have no direct positive evidence within the recent evidence window, so the thesis remains low confidence.

Why now: Potentially relevant because the article context references funding and lunar-measurement selection, but the reviewed sources provide no dated evidence or, so recency and sequence cannot be verified beyond the membership rationale tied to

Caveats: No current evidence is provided for cited Zero evidence available after recent evidence window despite the membership rationale. Funding and technology-selection references are article-context level only here.

194
Intelsat
lowweak
Opp 2
Risk 1

Thesis: The only positive indication in the reviewed sources are membership rationale stating Intelsat participated with Viasat in a Space Force mini-GEO satellite award, which could support a long-horizon government satcom opportunity if current and material, but no direct evidence or article summaries are available after the 90-day recent evidence window.

Why now: Why now is weak because coverage data shows 0 article IDs after recent evidence window and 0 evidence available after recent evidence window, so timing and durability cannot be validated from these reviewed sources.

Caveats: Membership rationale cites article IDs: and: but the reviewed sources provide no or summaries for them. Evidence recent evidence review shows kept_rows 0 and undated_rows_kept 0, so there is no usable direct evidence inside the ranking window. Cannot treat cohort membership as thesis attractiveness.

195
Intelsat General
lowweak
Opp 2
Risk 2

Thesis: Reviewed evidence membership rationale says Intelsat General was tied to a Space Force PTS-G satellite contract, which could support long-horizon defense-space opportunity, but no post-recent evidence window evidence or article summaries were available for scoring.

Why now: Why-now support is weak because coverage data shows zero article/evidence after the 90-day recent evidence window, so recency for the cited contract context cannot be validated from available evidence.

Caveats: Phase2 membership rationale references: but no representative article or evidence row is available after recent evidence window for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scored low due to evidence absence, not due to negative business evidence.

196
iQPS
lowweak
Opp 2
Risk 1

Thesis: Membership rationale says Rocket Lab secured a multi-launch agreement with iQPS for SAR satellites, which suggests iQPS may have meaningful constellation deployment activity over a 1 year+ horizon if current.

Why now: Why now is limited because the support is only referenced through membership rationale citing articles and, but the reviewed sources provide no or retained evidence after recent evidence window.

Caveats: No or article summaries are provided for cited support articles and. Coverage data shows zero retained evidence after recent evidence window. Potentially interesting launch-agreement signal cannot be scored highly without direct reviewed sources evidence.

197
Jacobs
lowweak
Opp 2
Risk 2

Thesis: Jacobs has evidence of a large Space Force Range Contract award worth up to $4 billion over 10 years, which would ordinarily support a positive thesis, but the relevant articles are dated June 3, 2025 and are outside the reviewed sources' 90-day recent evidence window, so current opportunity support is weak in these reviewed sources.

Why now: Why now is weak because the contract evidence is older. The reviewed sources cites Space Force and SpaceNews articles dated June 3, 2025, which are outside the 90-day evidence window

Caveats: Contract evidence exists but falls outside the selected 90-day recent evidence window. No direct positive or negative evidence remain after recent evidence filtering.

198
Jio Platforms
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources rationale says Jio Platforms is the vehicle for Reliance's planned multi-billion-dollar LEO satellite communications entry and planned network to compete with Starlink and Kuiper, which suggests long-horizon optionality if execution proceeds, but no underlying article evidence is provided in these reviewed sources output.

Why now: Why now is not well supported in the served evidence because no representative articles or direct evidence are available after recent evidence window despite the membership rationale referencing article IDs, and

Caveats: No representative articles or direct evidence are included in the reviewed sources output. Membership rationale is not a substitute for direct thesis evidence. Recency and event sequence cannot be judged from the missing article details.

199
Karman Holdings Inc.
lowweak
Opp 2
Risk 1

Thesis: Karman Holdings has modest contextual upside because the membership rationale says the reviewed sources placed it in broad space/defense and supply-chain articles and provided revenue facts, which may indicate operating scale or relevance to a durable strategic cycle, unavailable in reviewed sources). But there is no available direct positive evidence after recent evidence window, so this does not support more than a low opportunity score.

Why now: Why now is weak because there are no retained evidence after the 90-day cutoff date of March 29, 2026, despite multiple older considered articles.

Caveats: No current evidence is provided for and. Revenue facts are referenced only in the membership rationale, not available as direct evidence. Broad supply-chain context is weaker than company-specific contract or product evidence.

200
Korea Aerospace Industries (KAI)
lowweak
Opp 2
Risk 2

Thesis: Limited opportunity based only on the reviewed sources membership rationale that identifies CAS500-2 as an Earth observation satellite for KAI, indicating confirmed participation in a qualifying satellite activity but not providing a new catalyst, contract, backlog, or financial inflection.

Why now: Why now is weak because the reviewed sources say one article supported membership, article ID: but no, timing detail, or direct evidence were available after recent evidence window.

Caveats: No direct evidence or article summaries were available after recent evidence window. Membership support references article ID: without a in the reviewed sources.

Risk view

Showing rows 121-140 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
121
Aalyria Technologies
mediumweak
Opp 5
Risk 2

Thesis: The reviewed sources includes no material negative evidence; the main risk is thin grounding because the conclusion relies on one cited contract-related article without available detail or corroboration.

Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details.

Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace.

122
Agnikul
lowweak
Opp 3
Risk 2

Thesis: Risk is moderate because the reviewed sources explicitly says it lacks direct, specific evidence of rocket company operations or a funding/contract event for Agnikul itself in the included material, so the opportunity case is not adequately grounded.

Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence.

Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window.

123
Antaris Inc.
lowweak
Opp 2
Risk 2

Thesis: Current ranking risk is mostly uncertainty risk: without retained evidence inside the 90-day window, the reviewed sources does not establish whether the referenced programs are progressing, delayed, funded, or commercially material.

Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources.

Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment.

124
Apogeo Space
lowweak
Opp 4
Risk 2

Thesis: No material adverse evidence is provided, but the reviewed sources does not show contract economics, execution milestones, or customer traction, so commercialization risk remains.

Why now: The reviewed sources' membership rationale cites article: for the integration agreement and technical collaboration, but no article or direct evidence are included.

Caveats: Evidence is thin and article-level details are missing. Collaboration and integration agreements are weaker than revenue-bearing customer wins. Single-article support limits conviction.

125
Arctus Aerospace
lowweak
Opp 3
Risk 2

Thesis: The reviewed sources also explicitly says it is unclear whether Arctus is a true space company versus an atmospheric UAV company. That category ambiguity weakens thesis durability for this specific ranking universe, and no adverse company-specific event is otherwise available.

Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts.

126
Argotec
lowweak
Opp 1
Risk 2

Thesis: The main risk is evidentiary opacity: no kept structured positive or negative rows are available after recent evidence window, so business-state, traction, and durability are uncertain.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use.

Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources.

127
Astranis
lowmedium
Opp 4
Risk 2

Thesis: The evidence is mostly supporting article context rather than strong company-specific event extraction, so execution and conversion risk remain, but there is no direct adverse evidence available.

Why now: Recent dated context within the 90-day recent evidence window points to fresh financing and government program inclusion, both relevant for a 1 year+ horizon: Andromeda context on April 8, 2026 and funding context on June 19, 2026

Evidence
  • Published April 8, 2026: Space Force awarded 14 companies more than $1.8 billion in Andromeda contracts, and the listed companies included Astranis. defensedaily.com
  • Published June 19, 2026: Astranis raised a $300M Series E round and develops small communications satellites. spaceambition.substack.com

Caveats: Evidence is mainly supporting article context, which is weaker than direct event/fact evidence. An older 2025 article about a 2027 transportation deal exists, but it is outside the recent evidence window and not used as current proof.

128
Astranis Space Technologies
lowweak
Opp 2
Risk 2

Thesis: There is no direct adverse evidence, but the ranking is constrained by zero retained evidence after recent evidence window and potential duplication concerns in the broader article set.

Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale.

Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway.

129
Astrobotic Technology
lowweak
Opp 2
Risk 2

Thesis: No material adverse evidence is available in the reviewed sources, so a negative thesis is unsupported.

Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering.

Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative.

130
Astrolight UAB
lowweak
Opp 2
Risk 2

Thesis: The key risk is that the only described support is partner context, and the reviewed sources explicitly notes the relation row is context-only, leaving no strong basis for a company-specific positive or negative operating thesis.

Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status.

Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window.

131
Azista Industries Private Limited
lowweak
Opp 3
Risk 2

Thesis: The risk is that technical demonstration does not confirm scalable commercial adoption, contracts, or follow-on funding, and none of those are evidenced in the kept reviewed sources rows.

Why now: The only support cited is article in the membership rationale. Because the company coverage report shows zero articles after recent evidence window and zero evidence after recent evidence window, there is no robust timing catalyst beyond the historical demonstration narrative.

Caveats: Single-article support only, and not available as active evidence. No direct evidence on customer conversion, regulatory adoption, or funding. Private-company visibility is limited in these reviewed sources.

132
Azista Space
lowweak
Opp 2
Risk 2

Thesis: Risk is mostly uncertainty from minimal coverage: only one article was considered and zero evidence were available after recent evidence window, so durability, backlog, and execution status are unverified here.

Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum.

Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference.

133
Beijing Guodian High-Tech Technology Co
lowweak
Opp 4
Risk 2

Thesis: No direct adverse evidence is provided in the reviewed sources; main risk is limited visibility into commercialization and scale from the single referenced article.

Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale.

Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here.

134
Bellatrix Aerospace
lowweak
Opp 3
Risk 2

Thesis: Risk is primarily execution and verification uncertainty because the reviewed sources have zero available evidence after recent evidence window, so no current milestone, financing, or contract confirmation is available.

Why now: Why now is only moderate in theory because propulsion/platform partnerships can matter over a 1-year-plus horizon, but these reviewed sources does not provide recency-anchored evidence after recent evidence window.

Caveats: No direct evidence with available for citation. Technology differentiation is only inferred from membership rationale and is not independently corroborated in available evidence.

135
Blackstar Orbital
lowweak
Opp 2
Risk 2

Thesis: The main risk is evidence quality: the reviewed sources itself says the evidence is mostly partnership context and lacks direct company-specific operating detail, which weakens any durable 1 year+ thesis. There is still no material adverse event available after recent evidence window.

Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

136
Boeing
highstrong
Opp 8
Risk 2

Thesis: Source-specific risk is low because there is no available direct adverse evidence tied to Boeing's space thesis in this screen. The main offset is that the contract contributes to a long-cycle program with delivery beginning in 2031, so near-term financial realization is likely gradual rather than immediate, but that is not a negative event

Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance

Evidence
  • Boeing won a contract worth up to $2 billion to build two next-generation military communications satellites for the U.S. Space Force. spacenews.com
  • The $2 billion contract covers development, delivery and support for two additional MUOS narrow-band communications satellites; launches are no earlier than 2031 and 2032. breakingdefense.com
  • The U.S. Space Force selected Boeing for the MUOS Service Life Extension effort, valued at up to $2B, including two narrowband communications satellites. boeing.com

Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031.

137
Brightside Group S.A.
lowweak
Opp 2
Risk 2

Thesis: Risk is modest due to lack of current corroborating evidence rather than any adverse development. The reviewed sources contain no direct negative evidence.

Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content.

Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources.

138
CAS Space
lowweak
Opp 2
Risk 2

Thesis: The same rationale says there is little direct company-specific detail beyond inclusion in that group. Without available direct evidence after recent evidence window, the main risk is thesis fragility and inability to verify the claimed IPO/pre-IPO progression.

Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence.

139
Casimir Inc.
lowweak
Opp 1
Risk 2

Thesis: Casimir carries above-peer evidence risk in this screen because the sole cited support is described in the phase2 rationale as blog commentary, and the business fit to the target cohort is explicitly questioned. That weak grounding raises the risk of over-interpreting the financing mention.

Why now: There is no available article summary or evidence row after recent evidence window, so the only 'why now' is the uncitable phase2 statement about a seed round referenced by article id: without.

Caveats: The reviewed sources itself says the support article is blog commentary, weakening source quality. No citable or summary is provided for the referenced article id No evidence were available after recent evidence window in the served reviewed sources.

140
constellr
mediummedium
Opp 5
Risk 2

Thesis: Risk remains moderate because the evidence is still supporting article context rather than direct company disclosures about backlog, margins, or contracted demand, and no negative evidence is available. Execution risk remains around converting first-launch and funding momentum into durable commercial scale.

Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026.

Evidence
  • Article dated April 16, 2026 says constellr operates a proprietary satellite constellation measuring land surface temperatures from space to provide thermal intelligence for agriculture, defense, and climate operations. startupintros.com
  • The same April 16, 2026 article says the company launched its first satellite in January 2025 and closed a €37 million Series A funding round in February 2026. startupintros.com
  • The article says constellr has established itself as a primary thermal data provider for the European Union and serves 14 global regions. startupintros.com

Caveats: Evidence is external article context, not a direct company filing or contract announcement.